Advanced

DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.

Malmgren, Siri LU and Ahrén, Bo LU (2015) In Diabetologia 58(5). p.1091-1099
Abstract
Glucose-lowering therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with a low risk of hypoglycaemia. We hypothesise that DPP-4 inhibition prevents hypoglycaemia via increased glucagon counterregulation through the incretin hormone glucose-dependent insulinotropic polypeptide (GIP).
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetologia
volume
58
issue
5
pages
1091 - 1099
publisher
Springer Verlag
external identifiers
  • pmid:25660260
  • wos:000352644200026
  • scopus:84939984312
ISSN
1432-0428
DOI
10.1007/s00125-015-3518-7
language
English
LU publication?
yes
id
8004a49f-b1c2-4ad5-87af-9e8ba1fdabe2 (old id 5145222)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25660260?dopt=Abstract
date added to LUP
2015-03-04 19:11:05
date last changed
2017-07-02 03:21:23
@article{8004a49f-b1c2-4ad5-87af-9e8ba1fdabe2,
  abstract     = {Glucose-lowering therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with a low risk of hypoglycaemia. We hypothesise that DPP-4 inhibition prevents hypoglycaemia via increased glucagon counterregulation through the incretin hormone glucose-dependent insulinotropic polypeptide (GIP).},
  author       = {Malmgren, Siri and Ahrén, Bo},
  issn         = {1432-0428},
  language     = {eng},
  number       = {5},
  pages        = {1091--1099},
  publisher    = {Springer Verlag},
  series       = {Diabetologia},
  title        = {DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.},
  url          = {http://dx.doi.org/10.1007/s00125-015-3518-7},
  volume       = {58},
  year         = {2015},
}